Aptahem is active within biotechnology. The company conducts research and development of aptamer-based pharmaceuticals for the treatment of acute conditions caused by sepsis, blockage of blood vessels, stroke, and heart failure. Through early treatment, the pharmaceutical is intended to prevent damage to organs and tissue. A large part of the research is carried out in collaboration with partners within the industry. The company was founded in 2014 and is based in Malmö.

Quotes for Aptahem AB

Right Now

+/-
-0.01
%
−0,32%
Latest
3.1
High
3.12
Low
2.94
Volume
14 596
Turnover (SEK)
45 037
Market Value (MSEK)
17,6
Time (Latest trade)

Board

CEO

  • Mikael Lindstam

Chairperson of the Board

  • Bert Junno

Board

  • Johan Lindh
  • Mikael Lindstam
  • Theresa Comiskey Olsen

Videos

Largest Owners

Name Capital % Votes % Date
Avanza Pension 9,11 9,11 2024-03-26
Ivar Nordqvist 7,21 7,21 2024-03-26
Tuvedalen Ltd 4,90 4,90 2024-03-26
Gunvald Berger 3,85 3,85 2024-03-26
Nordnet Pensionsförsäkring 1,82 1,82 2024-03-26
Folke Harry Gerhard Ebbesson 1,34 1,34 2024-03-26
AB Svedala Finans 1,23 1,23 2024-03-26
Christian Pettersson 1,01 1,01 2024-03-26
Lövenblads Holding AB 0,94 0,94 2024-03-26
Tomas Adolfsson 0,79 0,79 2024-03-26
** Holdings by Modular Finance AB. Compiled and processed data from various sources, including Euroclear, Morningstar and the Swedish Financial Supervisory Authority.

Insider trading

*Source: Holdings by Modular Finance AB. Compiled and processed data from the Swedish Financial Supervisory Authority

Key Numbers

*Compiled data from Millistream